Diaceutics PLC Sub-optimal testing impacts on cancer patients

TIDMDXRX

Diaceutics PLC

01 November 2022

01 November 2022

Diaceutics PLC

("Diaceutics" or "the Company")

Release of study into inefficiencies within Personalised Medicine and its impact on cancer patients

Ground-breaking findings show that 64% of lung cancer patients in 2019 in the US missed getting the appropriate treatment

DXRX platform-enabled study highlights the need to address factors limiting the impact of personalised medicine within the cancer diagnosis and testing journey

Diaceutics PLC , (AIM: DXRX), a leading diagnostic commercialisation company which provides data, analytics and technology enabled services via its proprietary DXRX platform to the Precision Medicine market, announces the release of a large-scale study highlighting that a significant number of eligible patients treated for lung cancer did not receive access to the medicines most suitable to them, and therefore did not benefit from personalised medicine treatment.

The study, carried out in conjunction with a broad stakeholder group across the Personalised Medicine Coalition, was made possible by the Diaceutics Data Repository, a database consisting of 600 million patient records available on the DXRX platform. The study examined de-identified Medicare claims and laboratory data from 38,068 US-based patients diagnosed with advanced non-small cell lung cancer in 2019 to identify the operational inefficiencies in the diagnosis and testing journey across this dataset.

Overall, the publication identified that diagnostic testing-informed treatment strategies benefitted only 36% of the patients in the cohort. Of this group, 18% of patients did not receive the correct treatment as a result of inconclusive or false negative diagnostic results, and 29% of patients who had a successful diagnostic test were not prescribed the indicated treatment that they could have benefitted from.

A full list of the seven clinical practice gaps found from the study is included further below this announcement.

These findings represent the first step in understanding and pinpointing the nuances behind what prevents millions of people from getting the correct and timely healthcare they need. While the study was collected from US-based data, the findings are significant and reflective of the clinical gaps across other geographies and cancer types.

For the pharmaceutical community, the study highlights the need for greater investment into those technologies and data repositories which facilitate the wider application of personalised medicines. It also provides the basis for better understanding the action required by these stakeholders to tackle these clinical gaps, and to track progress going forward.

Diaceutics' Data Repository represents a world-leading diagnostic data set, combining multiple sources of information to build a complete picture of a typical patient's diagnostic journey. The mining capability of the DXRX platform allows the Company to identify Disease Diagnostic Pathways (DDPs) to determine the best possible testing journey for patients within a specific disease or disease area. The DDPs are both unique and proprietary to Diaceutics and are increasingly being developed for other therapeutic areas. As Diaceutics invests further in its platform, it will utilise access to the unrivalled wealth of data to continue removing testing hurdles and increasing patients' access to precision medicine.

The peer-reviewed study is published in JCO Precision Oncology. Further information on the study, titled "The Impact of Clinical Practice Gaps on the Implementation of Personalised Medicine in Advanced Non-Small Cell Lung Cancer", can be downloaded here.

Peter Keeling, Chief Executive Officer of Diaceutics, said:

"For the first time, through the use of large, real-world diagnostic testing data, we are able to verify the limitations within the diagnostic and treatment journey for the millions of cancer patients worldwide. These inefficiencies can, in the worst cases, inhibit patient recovery and reduce the quality of life for those who are terminally ill.

"Without the access to the highly specific data that can be generated by DXRX, it would have been difficult to generate these findings, which are clearly a cause for concern. Providing the specific data required for this study confirms our commitment to broadening the routine adoption, scale and efficiency of Personalised Medicine. The wider use of the DXRX platform itself and the DDPs that it generates will help ensure every patient is able to access the most appropriate treatment for their needs.

"More than ever, there is an urgent need for greater investment and a multi-stakeholder approach across labs, healthcare professionals and policy makers to ensure the significant benefits of personalised medicine are more widely felt. Diaceutics' proprietary DXRX platform is ideally placed to provide the core data to catalyse this collaborative approach."

Enquiries:

 
 
  Diaceutics PLC 
Peter Keeling, Chief Executive Officer                       Via Alma PR 
 
Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: [phone] 
                                                                    7600 
Ben Maddison 
Stewart Wallace 
Nick Adams 
 
Alma PR                                               Tel: [phone] 
                                                                    0205 
Caroline Forde                                   [e-mail] 
Kieran Breheny 
Matthew Young 
 

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network(R).

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

Diaceutics' data capability is one of the three key value drivers it has integrated into its unique DXRX platform alongside its global Lab network and product suite tailored for Precision testing.

About the Personalised Medicine Coalition:

The Personalised Medicine Coalition, a 501(c)3 organisation comprised of 14 distinct stakeholder groups within health care, promotes the understanding and adoption of Personalised Medicine concepts, services, and products to benefit patients and the health system.

For more information, please visit www.personalizedmedicinecoalition.org.

About JCO Precision Oncology

JCO Precision Oncology (JCO PO) is a peer-reviewed, online-only journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics and other biomarker-driven clinical care of patients with cancer. Innovative and timely scientific and educational content provide a deeper understanding of actionable cancer genomics, personalised translational and clinical oncology research, and recent treatment advances based on tumour molecular profiling.

The Impact of Clinical Practice Gaps on the Implementation of Personalised Medicine in Advanced Non-Small Cell Lung Cancer:

Seven ways in which clinical practice gaps limit the extent to which breakthroughs in Personalised Medicine benefit patients in clinical settings.

 
      Reason patients could not access precision medicine                             % of patients per 1,000 affected 
      clinicians did not prescribe a targeted or immuno-oncology therapy the 
       patient could have 
       benefitted from                                                                                            29.2 
                                                                                     --------------------------------- 
      genetic or genomic sequencing-based testing delivered inconclusive or 
       false-negative results, 
       usually for technical reasons or because of known testing limitations                                      18.3 
                                                                                     --------------------------------- 
      clinicians did not order the genetic or genomic sequencing-based testing 
       necessary to uncover 
       actionable biomarkers                                                                                      18.1 
                                                                                     --------------------------------- 
      clinicians' attempts to collect the necessary tumour tissue or blood samples 
       were unsuccessful                                                                                          14.5 
                                                                                     --------------------------------- 
      clinicians never attempted to collect the tumour tissue or blood samples 
       needed to uncover 
       actionable biomarkers                                                                                       6.6 
                                                                                     --------------------------------- 
      long turnaround times for test results prompted physicians and patients to 
       initiate treatment 
       regimens before testing results were available                                                                4 
                                                                                     --------------------------------- 
      the collected biospecimen did not contain enough tumour cells to allow for 
       testing to uncover 
       actionable biomarkers                                                                                       1.7 
                                                                                     --------------------------------- 
 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAMBBLTMTIJBBT

(END) Dow Jones Newswires

November 01, 2022 03:00 ET (07:00 GMT)